- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06103864
PD-L1 양성 국소 재발 수술 불가능 또는 전이성 삼중음성 유방암 환자를 대상으로 연구자가 선택한 화학요법과 Pembrolizumab 병용 요법을 Durvalumab 유무에 관계없이 Dato-DXd에 대한 제3상 연구
PD-L1 양성 환자에서 시험자가 선택한 화학요법(파클리탁셀, Nab-파클리탁셀 또는 젬시타빈 + 카보플라틴)과 펨브롤리주맙 병용 요법을 비교한 두르발루맙 유무에 관계없이 다토포타맙 데룩스테칸(Dato-DXd)의 제3상 공개 라벨 무작위 배정 연구 국소 재발성 수술 불가능 또는 전이성 삼중음성 유방암(TROPION-Breast05)
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
연구 개요
상태
정황
상세 설명
The primary objective of the study is to demonstrate superiority of Dato-DXd + durvalumab relative to ICC + pembrolizumab by assessment of PFS as assessed by BICR in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.
The study will be stratified based on geographic location (US/Canada/Europe vs. Dato-DXd monotherapy enrolling countries vs. rest of world), disease-free interval (DFI) history (de novo vs. prior DFI 6 to 12 months vs. prior DFI > 12 months), and prior PD-1/PD-L1 treatment for early stage TNBC (yes vs. no).
This study aims to see if Dato-DXd with durvalumab allows patients to live longer without their breast cancer getting worse, or simply to live longer, compared to patients receiving standard of care chemotherapy and pembrolizumab. This study is also looking to see how the treatment and the breast cancer affects patients' quality of life.
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: AstraZeneca Clinical Study Information Center
- 전화번호: 1-877-240-9479
- 이메일: information.center@astrazeneca.com
연구 연락처 백업
- 이름: AstraZeneca Breast Cancer Study Locator Service
- 전화번호: +1-877-400-4656
- 이메일: az-bcsl@careboxhealth.com
연구 장소
-
-
-
Cape Town, 남아프리카, 7570
- 모병
- Research Site
-
Johannesburg, 남아프리카, 2013
- 모병
- Research Site
-
Johannesburg, 남아프리카, 2196
- 모병
- Research Site
-
Johannesburg, 남아프리카, 2193
- 모병
- Research Site
-
Paarl, 남아프리카, 7646
- 모병
- Research Site
-
Pretoria, 남아프리카, 0081
- 모병
- Research Site
-
Pretoria, 남아프리카, 0081
- 완전한
- Research Site
-
-
-
-
-
Hsinchu, 대만, 300
- 모병
- Research Site
-
Kaohsiung City, 대만, 80756
- 모병
- Research Site
-
Taichung, 대만, 40447
- 모병
- Research Site
-
Tainan, 대만, 704
- 모병
- Research Site
-
Taipei, 대만, 100
- 모병
- Research Site
-
Taipei, 대만, 112
- 모병
- Research Site
-
Taipei, 대만, 10449
- 모병
- Research Site
-
Taipei, 대만, 11259
- 모병
- Research Site
-
Taoyuan, 대만, 333
- 모병
- Research Site
-
-
-
-
-
Busan, 대한민국, 49241
- 완전한
- Research Site
-
Daegu, 대한민국, 41404
- 모병
- Research Site
-
Goyang-si, 대한민국, 10408
- 모병
- Research Site
-
Seongnam-si, 대한민국, 13620
- 모병
- Research Site
-
Seoul, 대한민국, 03080
- 모병
- Research Site
-
Seoul, 대한민국, 06351
- 모병
- Research Site
-
Seoul, 대한민국, 05505
- 모병
- Research Site
-
Seoul, 대한민국, 03722
- 모병
- Research Site
-
Seoul, 대한민국, 06591
- 모병
- Research Site
-
Seoul, 대한민국, 02841
- 모병
- Research Site
-
Seoul, 대한민국, 06273
- 모병
- Research Site
-
-
-
-
-
Düsseldorf, 독일, 40479
- 빼는
- Research Site
-
Essen, 독일, 45136
- 빼는
- Research Site
-
Georgsmarienhütte, 독일, 49124
- 빼는
- Research Site
-
Hamburg, 독일, 20357
- 빼는
- Research Site
-
Hanover, 독일, 30625
- 빼는
- Research Site
-
Heidelberg, 독일, 69120
- 빼는
- Research Site
-
Heilbronn, 독일, 74078
- 빼는
- Research Site
-
Leipzig, 독일, 04103
- 빼는
- Research Site
-
-
-
-
-
CD Mexico, 멕시코, 04980
- 모병
- Research Site
-
Guadalajara, 멕시코, 44670
- 빼는
- Research Site
-
Guadalajara, 멕시코, 44638
- 모병
- Research Site
-
Mexico City, 멕시코, 0 3100
- 모병
- Research Site
-
Mexico City, 멕시코, 06760
- 모병
- Research Site
-
México, 멕시코, 04700
- 모병
- Research Site
-
Tuxtla Gutiérrez, 멕시코, 29090
- 모병
- Research Site
-
-
-
-
Alabama
-
Daphne, Alabama, 미국, 36526
- 모병
- Research Site
-
-
Arkansas
-
Springdale, Arkansas, 미국, 72762
- 모병
- Research Site
-
-
California
-
Duarte, California, 미국, 91010
- 빼는
- Research Site
-
Fountain Valley, California, 미국, 92708
- 아직 모집하지 않음
- Research Site
-
Glendale, California, 미국, 91204
- 모병
- Research Site
-
Sacramento, California, 미국, 95817
- 모병
- Research Site
-
Santa Rosa, California, 미국, 95403
- 빼는
- Research Site
-
-
Colorado
-
Aurora, Colorado, 미국, 80012
- 모병
- Research Site
-
Denver, Colorado, 미국, 80210
- 아직 모집하지 않음
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, 미국, 06510
- 모병
- Research Site
-
-
Florida
-
Altamonte Springs, Florida, 미국, 32701
- 아직 모집하지 않음
- Research Site
-
Jacksonville, Florida, 미국, 32256
- 빼는
- Research Site
-
Miami, Florida, 미국, 33176
- 모병
- Research Site
-
Palm Bay, Florida, 미국, 32909
- 빼는
- Research Site
-
Plantation, Florida, 미국, 33324
- 모병
- Research Site
-
-
Georgia
-
Atlanta, Georgia, 미국, 30318
- 정지된
- Research Site
-
-
Hawaii
-
Honolulu, Hawaii, 미국, 96819
- 빼는
- Research Site
-
-
Illinois
-
Chicago, Illinois, 미국, 60637
- 모병
- Research Site
-
Decatur, Illinois, 미국, 62526
- 빼는
- Research Site
-
Elmhurst, Illinois, 미국, 60126
- 빼는
- Research Site
-
Naperville, Illinois, 미국, 60540
- 빼는
- Research Site
-
-
Indiana
-
New Albany, Indiana, 미국, 47150
- 빼는
- Research Site
-
-
Iowa
-
Des Moines, Iowa, 미국, 50309
- 모병
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, 미국, 40503
- 빼는
- Research Site
-
Louisville, Kentucky, 미국, 40202
- 빼는
- Research Site
-
Louisville, Kentucky, 미국, 40207
- 빼는
- Research Site
-
-
Louisiana
-
Baton Rouge, Louisiana, 미국, 70809
- 모병
- Research Site
-
Baton Rouge, Louisiana, 미국, 70808
- 빼는
- Research Site
-
-
Maryland
-
Baltimore, Maryland, 미국, 21215
- 빼는
- Research Site
-
Columbia, Maryland, 미국, 21044
- 모병
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02111
- 빼는
- Research Site
-
Worcester, Massachusetts, 미국, 01655
- 빼는
- Research Site
-
-
Michigan
-
Detroit, Michigan, 미국, 48201
- 모병
- Research Site
-
Grand Rapids, Michigan, 미국, 49503
- 빼는
- Research Site
-
-
Minnesota
-
Saint Paul, Minnesota, 미국, 55109
- 모병
- Research Site
-
-
Mississippi
-
Hattiesburg, Mississippi, 미국, 39401
- 빼는
- Research Site
-
-
Missouri
-
St Louis, Missouri, 미국, 63129
- 모병
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87109
- 모병
- Research Site
-
-
New York
-
Albany, New York, 미국, 12206
- 빼는
- Research Site
-
New York, New York, 미국, 10065
- 모병
- Research Site
-
Stony Brook, New York, 미국, 11794-7263
- 모병
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45219
- 모병
- Research Site
-
Cincinnati, Ohio, 미국, 45245
- 모병
- Research Site
-
Cleveland, Ohio, 미국, 44195
- 모병
- Research Site
-
-
Pennsylvania
-
York, Pennsylvania, 미국, 17403
- 빼는
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, 미국, 02903
- 모병
- Research Site
-
-
Tennessee
-
Chattanooga, Tennessee, 미국, 37404
- 모병
- Research Site
-
Nashville, Tennessee, 미국, 37203
- 모병
- Research Site
-
-
Texas
-
Dallas, Texas, 미국, 75246
- 모병
- Research Site
-
Dallas, Texas, 미국, 75230
- 빼는
- Research Site
-
Dallas, Texas, 미국, 75246
- 빼는
- Research Site
-
El Paso, Texas, 미국, 79902
- 모병
- Research Site
-
Flower Mound, Texas, 미국, 75028
- 빼는
- Research Site
-
Fort Worth, Texas, 미국, 76104
- 빼는
- Research Site
-
Houston, Texas, 미국, 77054
- 빼는
- Research Site
-
Houston, Texas, 미국, 77090
- 빼는
- Research Site
-
Houston, Texas, 미국, 77098
- 빼는
- Research Site
-
Kingwood, Texas, 미국, 77339
- 빼는
- Research Site
-
McKinney, Texas, 미국, 75071
- 빼는
- Research Site
-
Sugar Land, Texas, 미국, 77479
- 모병
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, 미국, 22903
- 모병
- Research Site
-
Fairfax, Virginia, 미국, 22031
- 모병
- Research Site
-
Midlothian, Virginia, 미국, 23114
- 모병
- Research Site
-
Norfolk, Virginia, 미국, 23502
- 모병
- Research Site
-
Roanoke, Virginia, 미국, 24014
- 모병
- Research Site
-
-
Washington
-
Tacoma, Washington, 미국, 98405
- 모병
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, 미국, 53792
- 빼는
- Research Site
-
-
-
-
-
Da Nang, 베트남, 550000
- 모병
- Research Site
-
Hanoi, 베트남, 100000
- 모병
- Research Site
-
Ho Chi Minh City, 베트남, 700000
- 모병
- Research Site
-
Huế, 베트남, 530000
- 모병
- Research Site
-
Hồ Chí Minh, 베트남, 700000
- 모병
- Research Site
-
Viet Tri, 베트남, 35000
- 모병
- Research Site
-
Vinh, 베트남, 460000
- 모병
- Research Site
-
-
-
-
-
Barretos, 브라질, 14784-400
- 모병
- Research Site
-
Curitiba, 브라질, 80730-150
- 모병
- Research Site
-
Florianópolis, 브라질, 88034-000
- 모병
- Research Site
-
Goiânia, 브라질, 74000-000
- 모병
- Research Site
-
Itajaí, 브라질, 88301-220
- 모병
- Research Site
-
Porto Alegre, 브라질, 90035-003
- 모병
- Research Site
-
Recife, 브라질, 52010-075
- 모병
- Research Site
-
São Paulo, 브라질, 01246-000
- 모병
- Research Site
-
São Paulo, 브라질, 01317-001
- 모병
- Research Site
-
Teresina, 브라질, 64049-200
- 모병
- Research Site
-
-
-
-
-
Barcelona, 스페인, 8035
- 모병
- Research Site
-
Barcelona, 스페인, 08028
- 빼는
- Research Site
-
Granada, 스페인, 18016
- 모병
- Research Site
-
Hospitalet deLlobregat, 스페인, 08907
- 모병
- Research Site
-
Madrid, 스페인, 28007
- 모병
- Research Site
-
Madrid, 스페인, 28034
- 빼는
- Research Site
-
Pamplona, 스페인, 31008
- 모병
- Research Site
-
Santander, 스페인, 39008
- 모병
- Research Site
-
-
-
-
-
Singapore, 싱가포르, 169610
- 모병
- Research Site
-
Singapore, 싱가포르, 308433
- 모병
- Research Site
-
Singapore, 싱가포르, 217562
- 모병
- Research Site
-
Singapore, 싱가포르, 119228
- 빼는
- Research Site
-
-
-
-
-
CABA, 아르헨티나, 1425
- 모병
- Research Site
-
CABA, 아르헨티나, 1414
- 모병
- Research Site
-
CABA, 아르헨티나, C1425
- 빼는
- Research Site
-
CABA, 아르헨티나, C1113AAE
- 모병
- Research Site
-
Ciudad Autónoma Buenos Aires, 아르헨티나, C1430EFA
- 모병
- Research Site
-
Ciudad de Buenos Aires, 아르헨티나, C1015ABO
- 모병
- Research Site
-
Rosario, 아르헨티나, 2000
- 모병
- Research Site
-
San Nicolás de los Arroyos, 아르헨티나, B2900
- 빼는
- Research Site
-
-
-
-
-
Cardiff, 영국, CF14 2TL
- 모병
- Research Site
-
Chelsea, 영국, SW3 6JJ
- 모병
- Research Site
-
Leicester, 영국, Le5 4PW
- 모병
- Research Site
-
Liverpool, 영국, L7 8YA
- 종료됨
- Research Site
-
London, 영국, EC1A 7BE
- 모병
- Research Site
-
London, 영국, SW17 0QT
- 빼는
- Research Site
-
Oxford, 영국, OX3 7LE
- 정지된
- Research Site
-
Surrey, 영국, GU2 7XX
- 정지된
- Research Site
-
Sutton, 영국, SM2 5PT
- 모병
- Research Site
-
Taunton, 영국, TA1 5DA
- 모병
- Research Site
-
-
-
-
-
Bergamo, 이탈리아, 24127
- 모병
- Research Site
-
Empoli, 이탈리아, 50053
- 모병
- Research Site
-
Milan, 이탈리아, 20132
- 모병
- Research Site
-
Milan, 이탈리아, 20141
- 모병
- Research Site
-
Modena, 이탈리아, 41124
- 빼는
- Research Site
-
Naples, 이탈리아, 80131
- 모병
- Research Site
-
Padova, 이탈리아, 35128
- 모병
- Research Site
-
Reggio Emilia, 이탈리아, 42123
- 모병
- Research Site
-
Roma, 이탈리아, 00168
- 모병
- Research Site
-
Rozzano, 이탈리아, 20089
- 모병
- Research Site
-
-
-
-
-
Calicut, 인도, 673601
- 빼는
- Research Site
-
Chennai, 인도, 600031
- 모병
- Research Site
-
Jaipur, 인도, 302004
- 빼는
- Research Site
-
Kochi, 인도, 682027
- 빼는
- Research Site
-
Kolkata, 인도, 700160
- 빼는
- Research Site
-
Kottayam, 인도, 686008
- 모병
- Research Site
-
Marg Jaipur, 인도, 302004
- 모병
- Research Site
-
Mohali, 인도, 160055
- 모병
- Research Site
-
Mysuru, 인도, 570017
- 모병
- Research Site
-
Nagpur, 인도, 440001
- 모병
- Research Site
-
Nashik, 인도, 422009
- 모병
- Research Site
-
New Delhi, 인도, 11029
- 모병
- Research Site
-
New Delhi, 인도, 110075
- 모병
- Research Site
-
Puducherry, 인도, 605006
- 모병
- Research Site
-
Surat, 인도, 395002
- 모병
- Research Site
-
Thiruvananthapuram, 인도, 695011
- 모병
- Research Site
-
Vadodara, 인도, 391760
- 모병
- Research Site
-
Visakhapatnam, 인도, 530053
- 빼는
- Research Site
-
-
-
-
-
Akashi-shi, 일본, 673-8558
- 모병
- Research Site
-
Bunkyō City, 일본, 113-8431
- 모병
- Research Site
-
Bunkyō City, 일본, 113-8677
- 모병
- Research Site
-
Chiba, 일본, 260-8717
- 모병
- Research Site
-
Chūōku, 일본, 104-0045
- 모병
- Research Site
-
Fukuoka, 일본, 811-1395
- 모병
- Research Site
-
Fukushima, 일본, 960-1295
- 모병
- Research Site
-
Gifu, 일본, 501-1194
- 모병
- Research Site
-
Hidaka-shi, 일본, 350-1298
- 모병
- Research Site
-
Hiroshima, 일본, 734-8551
- 모병
- Research Site
-
Hiroshima, 일본, 730-8518
- 모병
- Research Site
-
Isehara-shi, 일본, 259-1193
- 모병
- Research Site
-
Kamogawa-shi, 일본, 296-8602
- 모병
- Research Site
-
Kashiwa, 일본, 277-8577
- 모병
- Research Site
-
Kitaadachi-gun, 일본, 362-0806
- 모병
- Research Site
-
Kumamoto, 일본, 860-8556
- 모병
- Research Site
-
Kurume-shi, 일본, 830-0011
- 모병
- Research Site
-
Kōtoku, 일본, 135-8550
- 모병
- Research Site
-
Matsuyama, 일본, 791-0280
- 모병
- Research Site
-
Nagoya, 일본, 466-8560
- 모병
- Research Site
-
Nagoya, 일본, 467-8602
- 모병
- Research Site
-
Niigata, 일본, 951-8566
- 모병
- Research Site
-
Nishinomiya-shi, 일본, 663-8501
- 모병
- Research Site
-
Okayama, 일본, 700-8558
- 모병
- Research Site
-
Osaka, 일본, 541-8567
- 모병
- Research Site
-
Osakasayama-shi, 일본, 589-8511
- 모병
- Research Site
-
Ota-shi, 일본, 373-8550
- 모병
- Research Site
-
Sapporo, 일본, 003-0804
- 모병
- Research Site
-
Sendai, 일본, 980-8574
- 모병
- Research Site
-
Shinagawa-ku, 일본, 142-8666
- 모병
- Research Site
-
Shinjuku-ku, 일본, 162-8655
- 모병
- Research Site
-
Shinjuku-ku, 일본, 160-0023
- 모병
- Research Site
-
Tsu, 일본, 514-8507
- 모병
- Research Site
-
Tsukuba, 일본, 305-8577
- 모병
- Research Site
-
Yokohama, 일본, 241-8515
- 모병
- Research Site
-
-
-
-
-
Anyang, 중국, 455000
- 모병
- Research Site
-
Beijing, 중국, 100044
- 모병
- Research Site
-
Beijing, 중국, 100142
- 모병
- Research Site
-
Bengbu, 중국, 233004
- 모병
- Research Site
-
Changchun, 중국, 130021
- 모병
- Research Site
-
Changsha, 중국, 410008
- 모병
- Research Site
-
Changsha, 중국, 410013
- 모병
- Research Site
-
Chengdu, 중국, 610000
- 모병
- Research Site
-
Chengdu, 중국, 610041
- 모병
- Research Site
-
Chongqing, 중국, 400030
- 빼는
- Research Site
-
Fuzhou, 중국, 350014
- 모병
- Research Site
-
Guangzhou, 중국, 510120
- 모병
- Research Site
-
Guangzhou, 중국, 510060
- 모병
- Research Site
-
Guangzhou, 중국, 510700
- 모병
- Research Site
-
Hangzhou, 중국, 310009
- 모병
- Research Site
-
Hangzhou, 중국, 310022
- 모병
- Research Site
-
Hangzhou, 중국, 310016
- 모병
- Research Site
-
Harbin, 중국, 150081
- 모병
- Research Site
-
Hefei, 중국, 230031
- 모병
- Research Site
-
Jinan, 중국, 250021
- 모집하지 않고 적극적으로
- Research Site
-
Meizhou, 중국, 514031
- 모병
- Research Site
-
Nanchang, 중국, 330009
- 모병
- Research Site
-
Nanjing, 중국, 210009
- 모병
- Research Site
-
Nanjing, 중국, 2100008
- 모병
- Research Site
-
Nanning, 중국, 530021
- 모병
- Research Site
-
Shandong, 중국
- 모병
- Research Site
-
Shanghai, 중국, 200025
- 모병
- Research Site
-
Shanghai, 중국, 200080
- 완전한
- Research Site
-
Shenyang, 중국, 110004
- 모병
- Research Site
-
Taiyuan, 중국, 030000
- 모병
- Research Site
-
Tianjin, 중국, 300000
- 모병
- Research Site
-
Wenzhou, 중국, 325000
- 모병
- Research Site
-
Wuhan, 중국, 430022
- 모병
- Research Site
-
Wuhan, 중국, 430079
- 모병
- Research Site
-
Xi'an, 중국, 710061
- 모병
- Research Site
-
Xiamen, 중국, 361003
- 모병
- Research Site
-
Xintai, 중국, 54031
- 모병
- Research Site
-
Xuzhou, 중국, 221009
- 모병
- Research Site
-
Zhanjiang, 중국, 524003
- 모병
- Research Site
-
Zhengzhou, 중국, 450008
- 모병
- Research Site
-
Zhengzhou, 중국, 450052
- 모병
- Research Site
-
-
-
-
Ontario
-
Barrie, Ontario, 캐나다, L4M 6M2
- 모병
- Research Site
-
Hamilton, Ontario, 캐나다, L8V 5C2
- 모병
- Research Site
-
Toronto, Ontario, 캐나다, M5G 2M9
- 모병
- Research Site
-
-
Quebec
-
Greenfield Park, Quebec, 캐나다, J4V 2H1
- 모병
- Research Site
-
Montreal, Quebec, 캐나다, H4A 3J1
- 모병
- Research Site
-
Montreal, Quebec, 캐나다, H2X 0A9
- 모병
- Research Site
-
Québec, Quebec, 캐나다, G1S 4L8
- 모병
- Research Site
-
-
Saskatchewan
-
Regina, Saskatchewan, 캐나다, S4T 7T1
- 모병
- Research Site
-
Saskatoon, Saskatchewan, 캐나다, S7N 4H4
- 모병
- Research Site
-
-
-
-
-
Bangkok, 태국, 10210
- 모병
- Research Site
-
Bangkok, 태국, 10400
- 모병
- Research Site
-
Bangkok, 태국, 10330
- 모병
- Research Site
-
Bangkok, 태국, 10700
- 모병
- Research Site
-
Chiang Mai, 태국, 50200
- 모병
- Research Site
-
Dusit, 태국, 10300
- 모병
- Research Site
-
Khon Kaen, 태국, 40002
- 모병
- Research Site
-
Songkhla, 태국, 90110
- 모병
- Research Site
-
-
-
-
-
Ankara, 터키 (Türkiye), 6200
- 모병
- Research Site
-
Ankara, 터키 (Türkiye), 06520
- 모병
- Research Site
-
Besevler Ankara, 터키 (Türkiye)
- 모병
- Research Site
-
Istanbul, 터키 (Türkiye), 34010
- 모병
- Research Site
-
Izmir, 터키 (Türkiye), 35575
- 빼는
- Research Site
-
Küçükçekmece, 터키 (Türkiye), 34295
- 모병
- Research Site
-
Samsun, 터키 (Türkiye), 55200
- 모병
- Research Site
-
-
-
-
-
Bialystok, 폴란드, 15-027
- 빼는
- Research Site
-
Bydgoszcz, 폴란드, 85-796
- 빼는
- Research Site
-
Gdansk, 폴란드, 80-952
- 모병
- Research Site
-
Gdynia, 폴란드, 81-519
- 빼는
- Research Site
-
Konin, 폴란드, 62-500
- 빼는
- Research Site
-
Krakow, 폴란드, 31-501
- 모병
- Research Site
-
Krakow, 폴란드, 31-115
- 빼는
- Research Site
-
Legnica, 폴란드, 59-220
- 빼는
- Research Site
-
Lodz, 폴란드, 90-302
- 모병
- Research Site
-
Lublin, 폴란드, 20-090
- 빼는
- Research Site
-
Przemyśl, 폴란드, 37-700
- 빼는
- Research Site
-
Warsaw, 폴란드, 02-781
- 모병
- Research Site
-
Wroclaw, 폴란드, 53-413
- 빼는
- Research Site
-
-
-
-
-
Lille, 프랑스, 59000
- 모병
- Research Site
-
Lyon, 프랑스, 69373
- 모병
- Research Site
-
Montpellier, 프랑스, 34298
- 모병
- Research Site
-
Paris, 프랑스, 75020
- 모병
- Research Site
-
Saint-Herblain, 프랑스, 44805
- 모병
- Research Site
-
Toulouse, 프랑스, 31059
- 모병
- Research Site
-
Vandœuvre-lès-Nancy, 프랑스, 54511
- 모병
- Research Site
-
Villejuif, 프랑스, 94800
- 모병
- Research Site
-
-
-
-
-
Bacolod, 필리핀 제도, 6100
- 모병
- Research Site
-
Cebu City, 필리핀 제도, 6000
- 모병
- Research Site
-
City of Muntinlupa, 필리핀 제도, 1780
- 모병
- Research Site
-
Manila, 필리핀 제도, 1000
- 모병
- Research Site
-
Quezon City, 필리핀 제도, 1112
- 모병
- Research Site
-
San Juan City, 필리핀 제도, 1502
- 모병
- Research Site
-
-
-
-
-
Camperdown, 호주, 2050
- 모병
- Research Site
-
Darlinghurst, 호주, 2010
- 완전한
- Research Site
-
Heidelberg, 호주, 3084
- 완전한
- Research Site
-
Melbourne, 호주, 3000
- 모병
- Research Site
-
Nedlands, 호주, 6009
- 모병
- Research Site
-
Waratah, 호주, 2298
- 빼는
- Research Site
-
-
-
-
-
Hong Kong, 홍콩, 999077
- 모병
- Research Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria
-
Histologically or cytologically documented locally recurrent inoperable, which cannot be treated with curative intent, or metastatic TNBC, as defined by the ASCO-CAP guidelines.
-
ECOG PS 0 or 1.
-
Participants are expected to provide an FFPE tumour sample collected from a locally recurrent inoperable or metastatic tumour. Alternatively, an archival FFPE tumour sample can be submitted; it must have been collected ≤ 3 years prior to the participant signing informed consent (screening start).
-
PD-L1 positive TNBC based on results from an appropriately validated investigational PD-L1 (22C3) assay (CPS ≥ 10) from a sponsor designated central laboratory.
-
No prior chemotherapy or other systemic anti-cancer therapy for metastatic or locally recurrent inoperable breast cancer.
- Patients with recurrent disease will be eligible if they have completed treatment for Stage I-III breast cancer, if indicated, and ≥6 months have elapsed between completion of treatment with curative intent and the first documented recurrence.
-
Eligible for one of the chemotherapy options listed as ICC (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin).
-
Measurable disease as per RECIST 1.1.
-
Adequate bone marrow reserve and organ function.
-
Male and female participants of childbearing potential must agree to use protocol-specified method(s) of contraception.
Key Exclusion Criteria
-
As judged by investigator, any evidence of diseases (such as severe or uncontrolled medical conditions including systemic diseases, uncontrolled hypertension, serious gastrointestinal conditions associated with diarrhoea, chronic diverticulitis or previous complicated diverticulitis, history of allogeneic organ transplant, and active bleeding diseases, ongoing and active infection, significant cardiac conditions, substance abuse, psychiatric illness/social situation or psychological conditions) which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
-
History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 2 years before Cycle 1 Day 1 and of low potential risk for recurrence.
-
Participants with a history of previously treated neoplastic spinal cord compression or treated, clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.
- Participants with treated clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.
-
Uncontrolled infection requiring IV antibiotics, antivirals or antifungals.
-
Active or uncontrolled hepatitis B or C virus infection.
-
Known HIV infection that is not well controlled.
-
Uncontrolled or significant cardiac disease.
-
History of non-infectious ILD/pneumonitis (including radiation pneumonitis) that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
-
Clinically severe pulmonary function compromise.
-
Clinically significant corneal disease.
-
Active or prior documented autoimmune or inflammatory disorders.
-
Prior exposure to any treatment including ADC containing a chemotherapeutic agent targeting topoisomerase I and TROP2-targeted therapy.
-
Any concurrent anti-cancer treatment.
-
Participants with a known severe hypersensitivity to PD-1/PD-L1 inhibitors or Dato-DXd.
-
Currently pregnant (confirmed with positive pregnancy test), breastfeeding or planning to become pregnant.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Dato-DXd + durvalumab
Arm 1: Dato-DXd + durvalumab |
Provided in 100mg vials. IV infusion. Experimental drug.
다른 이름들:
Provided in 500mg vials. IV infusion. Experimental drug.
다른 이름들:
|
|
활성 비교기: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab
Arm 2: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin) |
IV infusion. Active comparator. IV infusion. Active comparator. IV infusion. Active comparator. IV infusion. Active comparator. IV infusion. Active comparator. |
|
실험적: Dato-DXd
Arm 3: Dato-DXd |
Provided in 100mg vials. IV infusion. Experimental drug.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression Free Survival (PFS)
기간: From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The comparison will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anticancer therapy or clinically progresses prior to RECIST 1.1 progression. However, if the participant progresses or dies immediately after 2 or more consecutive missed visits, the participant will be censored at the time of the latest evaluable assessment prior to the 2 missed visits. The measure of interest is the HR of PFS. |
From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall Survival (OS)
기간: From randomisation until the date of death due to any cause (anticipated to be up to 64 months).
|
OS is defined as the time from randomisation until the date of death due to any cause. |
From randomisation until the date of death due to any cause (anticipated to be up to 64 months).
|
|
Objective Response Rate (ORR)
기간: From randomisation up until progression (anticipated to be up to 33 months).
|
ORR is defined as the proportion of participants who have a CR or PR, as determined by the BICR/investigator assessment, per RECIST 1.1. |
From randomisation up until progression (anticipated to be up to 33 months).
|
|
Duration of Response (DoR)
기간: From the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 33 months).
|
DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause. |
From the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 33 months).
|
|
Progression-Free Survival (PFS) by Investigator assessment
기간: From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 33 months).
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by investigator, or death due to any cause. |
From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 33 months).
|
|
Clinical Benefit Rate (CBR) at 24 weeks
기간: From randomisation up until progression, or the last evaluable assessment in the absence of progression (anticipated to be up to 33 months).
|
CBR at 24 weeks is defined as the percentage of participants who have a CR or PR or who have SD, per RECIST 1.1, as assessed by BICR/per investigator assessment and derived from the raw tumour data for at least 23 weeks after randomisation. |
From randomisation up until progression, or the last evaluable assessment in the absence of progression (anticipated to be up to 33 months).
|
|
Time to deterioration (TTD) in breast and arm symptoms in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
기간: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
TTD in breast symptoms and arm symptoms as measured by the arm symptoms scale from EORTC IL116 TTD is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. |
From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
|
Time to deterioration (TTD) in pain in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
기간: Time from the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
TTD in pain as measured by the EORTC IL199. |
Time from the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
|
Time to deterioration (TTD) in physical functioning in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
기간: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
TTD in physical function as measured by the PROMIS Short Form v2.0 - Physical Function 8c. |
From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
|
Time to deterioration (TTD) in GHS/QoL in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
기간: From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
TTD in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172. |
From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
|
|
Time to First Subsequent Therapy (TFST)
기간: From randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 64 months).
|
TFST is defined as the time from randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause. |
From randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 64 months).
|
|
Time to Second Subsequent Therapy (TSST)
기간: From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 64 months).
|
TSST is defined as the time from randomisation until the start date of the second subsequent anticancer therapy after discontinuation of first subsequent treatment, or death due to any cause. |
From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 64 months).
|
|
Progression Free Survival 2 (PFS2)
기간: From the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 64 months).
|
PFS2 will be defined as the time from the randomisation to the earliest progression event (following the initial progression), subsequent to first subsequent therapy, or death. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard clinical practice based on radiological or clinical progression. |
From the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 64 months).
|
|
Pharmacokinetics of Dato-DXd in combination with durvalumab
기간: From first dose to end of treatment (anticipated to be up to 33 months).
|
Concentration of Dato-DXd, total anti-TROP2 antibody, and DXd (payload) in plasma. |
From first dose to end of treatment (anticipated to be up to 33 months).
|
|
Immunogenicity of Dato-DXd in combination with durvalumab
기간: From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
|
Presence of antidrug antibodies for Dato-DXd (confirmatory results: positive or negative, titres). |
From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
|
|
Safety and tolerability of Dato-DXd + durvalumab as compared with ICC + pembrolizumab
기간: From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
|
Safety and tolerability will be evaluated in the safety population in terms of AEs. |
From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
|
공동 작업자 및 조사자
스폰서
협력자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- D7630C00001
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD 공유 기간
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD 공유 액세스 기준
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .